Amelia A Schabel

Title: Innovations of Amelia A. Schabel

Introduction

Amelia A. Schabel is a prominent inventor based in Indianapolis, IN (US). She has made significant contributions to the field of antibiotic research, holding a total of six patents. Her work focuses on developing glycopeptide antibiotics that target Gram-positive microorganisms.

Latest Patents

Among her latest patents is the development of A-82846-type glycopeptide antibiotics. These compounds are prepared by treating an antibiotic selected from A82846 components A, B, and C with trifluoroacetic acid. This process effectively removes specific groups attached to the disaccharide, enhancing the antibacterial activity of the compounds. Additionally, she has developed new N-alkyl and N-acyl derivatives of A82846A, A82846B, A82846C, and PA-42867-A. These new glycopeptide derivatives are particularly useful for treating susceptible bacterial infections.

Career Highlights

Amelia A. Schabel is currently employed at Eli Lilly and Company, where she continues her innovative work in antibiotic development. Her research has been instrumental in advancing treatments for bacterial infections, particularly those caused by Gram-positive microorganisms.

Collaborations

Throughout her career, Amelia has collaborated with notable colleagues, including Ramakrishnan Nagarajan and R. Michael Molloy. These partnerships have contributed to her success in the field of antibiotic research.

Conclusion

Amelia A. Schabel's contributions to antibiotic innovation highlight her role as a leading inventor in the pharmaceutical industry. Her work continues to impact the treatment of bacterial infections, showcasing the importance of innovation in healthcare.